(Alliance News) - GlaxoSmithKline PLC on Friday reported positive headline results from its Dreamm-2 study of belantamab mafodotin in multiple myeloma.
The study, which involved 196 patients with relapsed multiple myeloma - a type of bone marrow cancer - "met its primary objective and demonstrated a clinically meaningful overall response rate".
The drug maker noted that "multiple myeloma is the second most common blood cancer" and is not curable, though it can be treated.
The cancer often becomes resistant to treatment, and indeed patients in Dreamm-2 were refractory to anti-CD38 antibody treatment, an immunomodulatory drug, and a proteasome inhibitor.
The safety and tolerability of belantamab mafodotin was consistent with Dreamm-1, the first time in human trial of the drug. Dreamm-2 data will be used fore regulatory filing starting later in 2019.
Hal Barron, chief scientific officer and president of Research & Development at Glaxo, said: "I am pleased with the results of the DREAMM-2 study and excited about what these data could mean for patients with multiple myeloma who have exhausted other lines of treatment. We are on track to file belantamab mafodotin later this year and continue to investigate how it could help even more patients with this disease."
Glaxosmithkline (GSK)